Discovery of antibacterials and other bioactive compounds from microorganisms- evaluating methodologies for discovery and generation of non-ribosomal peptide antibiotics

Current Drug Targets

Volumn 12, Issue 11, 2011, Pages 1547-1559

  Witting, K ^a   Sussmuth R D ^a  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Antibacterials; Chemical screening; Combinatorial biosynthesis; Genetic engineering; Mutasynthesis; Peptides; Precursor directed biosynthesis; Screening approaches

Indexed keywords

A 40926; A 47937; ABYSSOMYCIN C; ANTIINFECTIVE AGENT; BACITRACIN; BALHIMYCIN; CHLOROEREMOMYCIN; COMPLESTATIN; ENNIATIN; FENGYCIN; NATURAL PRODUCT; ORFAMIDE A; POLYPEPTIDE ANTIBIOTIC AGENT; PRISTINAMYCIN; SURFACTIN; TEICOPLANIN; TYROCIDINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; COMBINATORIAL CHEMISTRY; DRUG DESIGN; DRUG ISOLATION; DRUG SCREENING; DRUG SYNTHESIS; EVALUATION; GENETIC ENGINEERING; GENOMICS; METHODOLOGY; NONHUMAN; POLYMERASE CHAIN REACTION; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; MODELS, MOLECULAR;

EID: 80054072494     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011798109527     Document Type: Review

References (71)

1. Fleming A. Classics in infectious diseases: on the antibacterial action of cultures of a penicillium, with special references to their use in the isolation of B. influenzae by A. Fleming reprinted from the British Journal of Experimental Pathology 1929; 10: pp. 226-36. Rev Infect Dis 1980; 2(1): 129-39.
2. Chain E, Florey HW, Gardener AD, et al. Penicillin as a chemotherapeutic agent. Lancet. 1940; 236(6104): 226-8.
3. Corre C, Challis GL. Heavy tools for genome mining. Chem Biol 2007; 14(1): 7-9.
4. Nussbaum FV, Brands M, Hinzen H, Weigand S, Häbich D. Antibacterial natural products in medicinal chemistry-exodus or revival? Angew Chem Int Ed 2006; 45(31): 5072-129.
5. Fox JL. The business of developing antibacterials. Nature Biotechnology 2006; 24(12): 1521-8.
6. Hancock RE. The end of an era. Nat Rev Drug Discov 2007; 6: 28.
7. Newman DJ. Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J Med Chem 2008; 51(9): 2589-99.
8. Williams DH. The glycopeptide story-how to kill deadly 'superbugs'. Nat Prod Rep. 1996; 13(6): 469-77.
9. Breinbauer R, Vetter IR, Waldmann H. From protein domains to drug candidates--natural products as guiding principles in the design and synthesis of compound libraries. Angew Chem Int Ed 2002; 41(16): 2888-90.
10. Coates ARM, Hu Y. Novel approaches to developing new antibiotics. Br J Pharmacol. 2007; 152(8): 1147-54.
11. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev 2005; 4(3): 206-20.
12. Zerliky M, Challis GL. Strategies for the discovery of new natural products by genome mining. ChemBioChem 2009; 10(4): 625-33.
13. Rognan D. Chemogenomic approaches to rational drug design. Br J Pharmacol 2007; 152(1): 38-52.
14. Evans BE. Methods for drug discovery: development of potent, selective, orally effective chloecystokinin antagonists. J Med Chem 1988; 31(12).
15. Grünewald J, Marahiel MA. Chemoenzymatic and templatedirected synthesis of bioactive macrocyclic peptides. Microbiol Mol Biol Rev 2006; 70(1): 121-46.
16. Felnagle EA, Jackson EE, Chan YA, et al. Nonribosomal peptide synthetases involved in the production of medicinally relevant natural products. Mol Pharmaceuticals 2008; 5(2): 191-211.
17. Graberly S, Thierecke R, Sattler I. In: The Role of Natural Products in Drug Discovery Jena, Germany: Ernst Schering Res Found 2000; pp. 217-52.
18. Zhang W, Tang Y. Combinatorial biosynthesis of natural products. J Med Chem. 2008; 51(9): 2629-33.
19. Baltz RH. Molecular engineering approaches to peptide, polyketide and other antibiotics. Nature Biotechnology 2006; 24(12): 1533-40.
20. Peiera DA, Williams JA. Origin and evolution of high throughput screening. Br J Pharmacol. 2007; 152(1): 53-61.
21. Pelaez F. The historical development of antibiotics from microbial natural products--can history repeat? Biochem Pharmacol 2006; 71(7): 981-90.
22. Newman DJ, Cragg GM, Snader KM. Natural products as sources for new drugs over the period 1981-2002. J Nat Prod 2003; 66(7): 1022-2037.
23. McCafferty DG, Cudic P, Frankel BA, et al. Chemistry and biology of the ramoplanin family of peptide antibiotics. Biopolymers 2002; 66(7): 261-84.
24. Ventura M, Canchaya C, Tauch A, et al. Genomics of actinobacteria: tracing the evolutionary history of an ancient phylum. Microbiol Mol Biol Rev 2007; 71(3): 495-548.
25. Bentley SD, Chater KF, Cerdeno-Tarraga AM, et al. Complete genome sequencing of the model actinomycete Streptomyces coelicolor A3(2). Nature 2002; 417(6885): 141-7.
26. Projan SJ. New (and not so new) antibacterial targets--from where and when will the novel drugs come? Curr Opin Pharmacol 2002; 2(5): 513-22.
27. Schimana J, Gebhardt K, Höltzel A, et al. Arylomycins A and B, new biaryl-bridged lipopeptide antibiotics produced by Streptomyces sp Tü6075. J Antibiot (Tokyo) 2002; 55(6): 565-70.
28. Paetzel M, Goodall JJ, Kanin M, Dalbey RE, Page MGP. Crystallographic and biophysical analysis of a bacterial signal peptidase in complex with lipopeptide-based inhibitor. J Biol Chem 2004; 279(29): 30781-90.
29. Tschantz WR, Sung M, Delgado-Parkin VM, Enalbey R. A serine and lysine residue implicated in the catalyrtic mechanism of the Eschericia coli leader peptidase. J Biol Chem 1993; 268(36): 27349-54.
30. Riedlinger J, Riecke A, Zähner H, et al. Abyssomicins, inhibitors of the para-aminobenzoic acid pathway produced by the marine Verrucosispora strain AB-18-032. J Antibiot 2004; 57(4): 271-9.
31. Bister B, Bischoff D, Ströbele M, et al. Abyssomycin C--a polycyclic antibiotic from a marine Verrucosispora strain as an inhibitor of the p-Aminobenzoic/Tetrahydrofolate biosynthesis pathway. Angew Chem Int Ed 2004; 43(19): 2574-6.
32. Keller S, Nicholson G, Drahl C, et al. Abyssomicins G and H atrop-Abyssomicin C from the marine Verrucosispora strain AB- 18-032. J Antibiot 2007; 60(6): 391-4.
33. Fleischman RD, Adams MD, White D, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 1995; 269(5223): 496-512.
34. McDevitt D, Rosenberg M. Exploiting genomics to discover new antibiotics. Trend Microbiol. 2001; 9: 611-7.
35. Field D, Hughes J, Moxton ER. Using the genome to understand pathogenicity. Methods Mol Biol 2004; 226: 261-87.
36. Pelzer S, Vente A, Bechthold A. Novel natural compounds obtained by genome-based screening and genetic engineering Curr Opin Drug Discov Devel 2005; 8(2): 228-38.
37. Challis GL. Mining microbial genomes for new natural products and biosynthetic pathways. Microbiology 2008; 154(6): 1555-69.
38. Challis G. Genome mining for novel product discovery. J Med Chem 2008; 51(9): 2618-28.
39. Pucci MJ. Use of genomics to select antibacterial targets. Biochem Pharmacol 2006; 71(7): 1066-72.
40. Hornung A, Bertazzo M, Dziarnowski A, et al. A genomic screening approach for the structure-guided identification of drug candidates from natural sources. ChemBioChem 2007; 8(7): 757-66.
41. Gross H, Stockwell VO, Henkels MD, et al. The genomisotopic approach: a systematic method to isolate products of orphan biosynthetic gene clusters. Chem Biol 2007; 14(1): 53-63.
42. Clardy J, Fischbach MA, Walsh CT. New antibiotics from bacterial natural products. Nat Biotechnol 2006; 24(12): 1541-50.
43. Thiercke R, Rohr J. Biological variation of microbial metabolites by precursor-directed biosynthesis. Appl Microbiol Biotechnol 1993; 10: 265-89.
44. Kirschning A, Taft F, Knobloch T. Total synthesis approaches to natural product derivatives based on the combination of chemical synthesis and metabolic engineering. Org Biomol Chem 2007; 5(20): 3245-59.
45. Powell A, Borg M, Amir-Heidari B, et al. Engineered biosynthesis of nonribosomal lipopeptides with modified fatty acid side chains. J Am Chem Soc 2007; 129: 15182-91.
46. Maison W. Natural products research: renaissance with strengthend integration of biology and chemistry. Angew Chem Int Ed 2006; 45(19): 3000-2.
47. Butz D, Schmiederer T, Haddatsch B, Wohlleben W, Süssmuth RD. Module extension of a non-ribosomal peptide synthetase of the gylcopeptide antibiotic balhymycin produced by Amycolatopsis balhimycina. ChemBioChem 2008; 9(8): 1195-200.
48. Sieber S, Marahiel MA. Molecular mechanisms underlying nonribosomal peptide synthesis. Chem Rev 2005; 105(1): 715.
49. Finking R, Marahiel MA. Biosynthesis of nonribosomal peptides. Annu Rev Microbiol 2004; 58: 453-88.
50. Nguyen KT, Ritz D, Gu JQ, et al. Combinatorial biosynthesis of novel antibiotics related to daptomycin. PNAS 2006; 103(6): 17462-7.
51. Mootz HD, Schwarzer D, Marahiel MA. Ways of assembly complex natural products on molecular nonribosomal peptide synthetases. ChemBioChem 2002; 3(6): 490-504.
52. Wang J, Suissun SM, Young K, et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006; 441(7091): 358-61.
53. Wolter F, Schoof S, Süssmuth RD. Synopsis of structural, biosynthetic, and chemical aspects of glycopeptide antibiotics. Top Curr Chem 2006; 267: 143-85.
54. Williams DH, Bardseley B. The vancomycin-group of antibiotics and the fight against resistant bacteria. Angew Chem Int Ed 1999; 38(9): 1172-93.
55. Hubbard BK, Walsh CT. Vancomycin's assembly: nature's way. Angew Chem Int Ed 2003; 42(7): 730-65.
56. Süssmuth RD, Wohlleben W. The biosynthesis of glycopeptide antibiotics-a model for complex non-ribosomal synthesized peptide secondary metabolites. Appl Microb Biotech 2004; 63: 344.
57. Müller J, Feifel SC, Schmiederer T, Roder K, Süssmuth RD. In vitro synthesis of a new cyclodepsipeptide of the pf1022-type: probing the a-d-hydroxy acid tolerance of PF1022- synthetase. ChemBioChem 2009; 10(2): 323-8.
58. Kahne D, Leimkühler C, Lu W, Walsh CT. Glycopeptide and lipoglycopeptide antibiotics. Chem Rev 2005; 105(2): 425-48.
59. Mootz HD, Kessler N, Linne U, et al. Decreasing the ring size of a cyclic nonribosomal peptide antibiotic by in-frame module deletion in biosynthetic genes. J Am Chem Soc 2002; 124(37): 10980-1.
60. Wilkinson B, Micklefield J. Mining and engineering naturalproduct biosynthesis pathways. Nat Chem Biol 2007; 3(7): 379-86.
61. Wenzel SC, Meier P, Binz T, Mahmud T. Nonribosomal peptide biosynthesis: point mutations and module skipping lead to chemical diversity. Angew Chem Int Ed 2006; 45(14): 2296-301.
62. Leeb M. Antibiotics: a shot in the arm. Nature 2004; 431(7011): 892-3.
63. Tanovic A, Samel SA, Essen L-O, Marahiel MA. crystal structure of the termination module of a nonribosomal peptide synthetase. Science 2008; 321(5889): 659-63.
64. Müller M. Chemical diversity through biotransformations. Curr Opin Biotechnol 2004; 15(6): 591-8.
65. Trauger JW, Rah M, Kohlie RM, et al. Peptide cyclization catalyzed by the thioesterase domain of thyrocidine synthetase. Nature 2000; 407(6801): 215.
66. Feifel SC, Schmiederer T, Hornbogen T, Süssmuth RD, Zocher R. In vitro synthesis of new enniatins: probing the alpha-D-hydroxy carboxylic acid binding pocket of the multienzyme enniatin synthetase. ChemBioChem 2007; 8(15): 1767-70.
67. Hermann M, Zocher R, Haese A. enniatin production by fusarium strains and its effect on potato tuber tissue. Appl Environ Microbiol 1996; 62(2): 393-8.
68. Xu Y, Kithsiri-Wijratne EM, Espinosa-Artiles P, Lesile-Guatilaka AA, Molnar I. Combinatorial mutasynthesis of scrambled beauvericins, cyclooligomer-depsipeptide cell migration inhibitors from Beauveria bassiana. ChemBioChem 1996; 10(2): 345-54.
69. Xu Y, Orozco R, Kithsiri-Wijratnje E-M, et al. Biosyntheis of the cyclooligomer depsipeptide Beauvericin, a virulence factor of the entomopathogenic fungus Beauveris bassiana. Chem Biol 2008; 15(9): 898-907.
70. Schneider T, Kruse T, Wimmer R, et al. Plectensin, a fungal defensin targets the bacterial cell wall precursor lipid-II. Science 2010; 328(5982): 1168-72.
71. Müller W, Schmieder T, Ensle P, S̈ssmuth RD. In vitro biosynthesis of prepeptide of type-III-lantibiotic labyrinthopeptin A2 including formation of a C-C bond as a post-translational modification. Angew Chem Int Ed 2010; 49(13): 2436-40.